BlackRock Discloses Significant Passive Stake in Lyell Immunopharma
Ticker: LYEL · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a big passive stake in Lyell Immunopharma.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in Lyell Immunopharma, Inc. as of December 31, 2023. This filing indicates BlackRock's passive ownership, meaning they are not seeking to influence Lyell's management. For investors, this signals that a large institutional investor sees value in Lyell Immunopharma, potentially lending credibility to the stock, but also means a large block of shares is held by a single entity, which could impact liquidity or future price movements if BlackRock were to significantly alter its position.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a notable position in Lyell Immunopharma, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally doesn't pose immediate risks to the company or its shareholders.
Analyst Insight
An investor should note BlackRock's passive stake as a sign of institutional interest, but understand it doesn't imply active management changes. Further research into Lyell Immunopharma's fundamentals and BlackRock's overall investment strategy would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Lyell Immunopharma, Inc. (company) — the subject company (issuer) in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the 'reporting person' in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
What is the 'subject company' or 'issuer' in this filing?
The subject company, or issuer, is Lyell Immunopharma, Inc., identified by CIK 0001806952.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Lyell Immunopharma, Inc. is 55083R104.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Lyell Immunopharma, Inc. (LYEL).